Single Center, Open-label, Non-randomized, Non-placebo-controlled Study to Investigate the Metabolism, Excretion Pattern, Mass Balance, Safety, Tolerability and Pharmacokinetics After Single Administration of 200 mg [14C]Rogaratinib (Oral Solution) in Healthy Male Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 02 Jul 2018
At a glance
- Drugs Rogaratinib (Primary)
- Indications Breast cancer; Solid tumours; Urogenital cancer
- Focus Pharmacokinetics
- Sponsors Bayer
- 22 May 2018 Planned primary completion date changed from 17 May 2018 to 24 May 2018.
- 27 Apr 2018 Planned number of patients changed from 6 to 8.
- 27 Apr 2018 Status changed from not yet recruiting to active, no longer recruiting.